Chandra P. Belani, MD

Chandra P. Belani, MD, deputy director, Penn State Hershey Cancer Institute, Miriam Beckner Distinguished Professor of Medicine, Penn State Hershey College of Medicine, talks about how immunotherapies targeting PD-L1 and PD-1 are showing activity in lung cancer.

Belani says that immunotherapies in lung cancer are only currently approved for use in the second-line setting and should be in oncologists&rsquo; armamentarium. The drugs that are currently approved are nivolomab, which is approved for squamous cell carcinoma and non-squamous non-small cell lung cancer (NSCLC), as well as pembrolizumab.

Belani adds that pembrolizumab is preferential when treating patients with a high PD-L1 expression in their tumors.

Videos

Dr. Chandra P. Belani on the Importance of Immunotherapies in Treating Lung Cancer

Chandra P. Belani, MD, Deputy Director, Penn State Hershey Cancer Institute, Miriam Beckner Distinguished Professor of Medicine, Penn State Hershey College of Medicine, discusses treating older patients who have non-small cell lung cancer.

the treatment of older patients with NSCLC > >

Articles

Chandra P. Belani, MD, Deputy Director, Penn State Hershey Cancer Institute, Miriam Beckner Distinguished Professor of Medicine, Penn State Hershey College of Medicine, discusses treating older patients who have non-small cell lung cancer

Treating Older Patients With NSCLC

Chandra P. Belani, MD, Deputy Director, Penn State Hershey Cancer Institute, Miriam Beckner Distinguished Professor of Medicine, Penn State Hershey College of Medicine, discusses the VEGF-targeted agent nintedanib (BIBF 1120).

Nintedanib was studied in combination with docetaxel in a phase III randomized study of NSCLC

This study showed an improvement in progression-free survival

In a second trial, in combination with pemetrexed, nintedanib showed no benefit to progression-free survival

Chandra P. Belani, MD, discusses the VEGF-targeted agent nintedanib (BIBF 1120).

Treating NSCLC With Nintedanib

Chandra P. Belani, MD, Deputy Director, Penn State Hershey Cancer Institute, Miriam Beckner Distinguished Professor of Medicine, Penn State Hershey College of Medicine, discusses the treatment of subgroups of patients with lung cancer.

Chandra P. Belani, MD, from the Penn State Hershey Cancer Institute, discusses the treatment of subgroups of patients with lung cancer.

Chandra P. Belani, MD | Authors

Articles

Dr. Chandra P. Belani on the Importance of Immunotherapies in Treating Lung Cancer

Treating Older Patients With NSCLC

Treating NSCLC With Nintedanib

The Treatment of Lung Cancer Subgroups